|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.36/-3.73
|
企業價值
1.36B
|
資產負債 |
每股賬面淨值
11.62
|
現金流量 |
現金流量率
--
|
損益表 |
收益
20.72M
|
每股收益
0.04
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/21 13:40 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310. |